Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

Withdrawn1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

withdrawn133%
recruiting133%
unknown133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_1

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

NCT06634394
unknownphase_1

Study of APVO436 in Patients With AML or MDS

NCT03647800
withdrawnphase_1

Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

NCT04973618

Clinical Trials (3)

Showing 3 of 3 trials
NCT06634394Phase 1

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Recruiting
NCT03647800Phase 1

Study of APVO436 in Patients With AML or MDS

Unknown
NCT04973618Phase 1

Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3